Biotechnology company, bluebird bio, Inc. (NASDAQ:BLUE) announced late Friday that the Food and Drug Administration approved its gene therapy for a rare neurodegenerative disease.
What Happened: The FDA granted accelerated approval for Skysona, aka eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD), the Somerville, Massachusetts-based company said in a statement.
